Skip to main content
. 2013 Oct 10;7(10):e2479. doi: 10.1371/journal.pntd.0002479

Figure 3. Identification of biomarkers associated with clinical progression of HAM/TSP.

Figure 3

(A) Five CSF marker candidates (CXCL10, CXCL9, neopterin, cell count, and anti-HTLV-1 antibody titer) and four blood marker candidates (proviral load in PBMCs, serum sIL-2R, plasma CXCL9, and plasma CXCL10) were compared among a cohort of patients called the Training Set (deteriorating HAM/TSP, n = 11; stable HAM/TSP, n = 14). Data is shown for the top eight CSF markers ranked according to the significance of the difference between the deteriorating and stable subjects. Black circles indicate patients with particularly rapidly progressive HAM/TSP. Horizontal bars indicate the median values. The Mann-Whitney U-test was used for statistical analysis. (B) ROC analysis was employed to assess the sensitivities and specificities of the nine markers listed above for discriminating deteriorating HAM/TSP patients from stable patients. AUC = area under the ROC curve; 95% CI = 95% confidence interval.